Art Bioscience
Rehovot, Israel· Est.
Israeli mRNA biotech developing novel DMD therapies using proprietary lipid nanoparticle delivery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli mRNA biotech developing novel DMD therapies using proprietary lipid nanoparticle delivery.
Duchenne Muscular DystrophyGenetic Musculoskeletal Disorders
Technology Platform
Proprietary lipid nanoparticle (LNP) delivery of modified mRNA for protein replacement and CRISPR‑Cas9 mRNA for transient gene editing.
Opportunities
Leverages rapid mRNA advances to address a high‑unmet‑need orphan disease, with potential expansion to other genetic musculoskeletal disorders.
Risk Factors
Technical challenges in systemic muscle delivery, regulatory uncertainty for mRNA‑based protein replacement, and strong competition from established gene‑therapy firms.
Competitive Landscape
Competes with Sarepta, Solid Biosciences, and Editas, but differentiates through its proprietary LNP platform and dual protein‑replacement/gene‑editing strategy.